Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Telaprevir enhances ribavirin-induced anaemia through renal function impairment.

Cotte L, Barrail-Tran A, Vincent C, Valantin MA, Fournier I, Lacombe K, Chevaliez S, Aboulker JP, Taburet AM, Molina JM; the ANRS HC; study group.

Antivir Ther. 2014 Jan 6. doi: 10.3851/IMP2929. [Epub ahead of print]

PMID:
25560644
2.

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.

Bhatt NB, Baudin E, Meggi B, da Silva C, Barrail-Tran A, Furlan V, Grinsztejn B, Bonnet M, Taburet AM; ANRS 12146/12214-CARINEMO Study Group.

J Antimicrob Chemother. 2015 Jan;70(1):225-32. doi: 10.1093/jac/dku348. Epub 2014 Sep 18.

3.

Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.

Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, Taburet AM; ANRS 12146-CARINEMO Study Group.

Antimicrob Agents Chemother. 2014 Jun;58(6):3182-90. doi: 10.1128/AAC.02379-13. Epub 2014 Mar 24.

4.

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.

Lan NT, Thu NT, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, Lien TT, Borand L, Quillet C, Connolly C, Lagarde D, Pym A, Lienhardt C, Dung NH, Taburet AM, Harries AD.

PLoS One. 2014 Jan 22;9(1):e84866. doi: 10.1371/journal.pone.0084866. eCollection 2014.

5.

Characterization of binding of raltegravir to plasma proteins.

Barau C, Furlan V, Yazdanpanah Y, Fagard C, Molina JM, Taburet AM, Barrail-Tran A.

Antimicrob Agents Chemother. 2013 Oct;57(10):5147-50. doi: 10.1128/AAC.00625-13. Epub 2013 Jul 15.

6.

Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.

Chauvin B, Drouot S, Barrail-Tran A, Taburet AM.

Clin Pharmacokinet. 2013 Oct;52(10):815-31. doi: 10.1007/s40262-013-0075-4. Review.

PMID:
23703578
7.

Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.

Parienti JJ, Barrail-Tran A, Duval X, Nembot G, Descamps D, Vigan M, Vrijens B, Panhard X, Taburet AM, Mentré F, Goujard C.

Antimicrob Agents Chemother. 2013 May;57(5):2265-71. doi: 10.1128/AAC.02605-12. Epub 2013 Mar 4.

8.

Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.

Fan-Havard P, Liu Z, Chou M, Ling Y, Barrail-Tran A, Haas DW, Taburet AM; ANRS12154 Study Group.

Antimicrob Agents Chemother. 2013 May;57(5):2154-60. doi: 10.1128/AAC.02294-12. Epub 2013 Mar 4.

9.

External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.

Rekić D, Röshammar D, Bergstrand M, Tarning J, Calcagno A, D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Äbelö A.

AAPS J. 2013 Apr;15(2):308-15. doi: 10.1208/s12248-012-9440-8. Epub 2012 Dec 7.

10.

Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F; ANRS 134–COPHAR 3 Study Group.

Clin Pharmacol Ther. 2012 Nov;92(5):575-83. doi: 10.1038/clpt.2012.137. Epub 2012 Oct 3.

11.

Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.

Barau C, Furlan V, Debray D, Taburet AM, Barrail-Tran A.

Br J Clin Pharmacol. 2012 Sep;74(3):515-24. doi: 10.1111/j.1365-2125.2012.04213.x.

12.

[Evidence-based therapeutic drug monitoring for indinavir].

Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 May-Jun;66(3):239-46. doi: 10.2515/therapie/2011035. Epub 2011 Aug 9. Review. French.

PMID:
21819808
13.

[Evidence-based therapeutic drug monitoring of lopinavir].

Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 May-Jun;66(3):231-8. doi: 10.2515/therapie/2011034. Epub 2011 Aug 9. Review. French.

PMID:
21819807
14.

Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.

Barau C, Barrail-Tran A, Hemerziu B, Habes D, Taburet AM, Debray D, Furlan V.

Liver Transpl. 2011 Oct;17(10):1152-8. doi: 10.1002/lt.22364.

15.

Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.

Goldwirt L, Braun J, de Castro N, Charreau I, Barrail-Tran A, Delaugerre C, Raffi F, Lascoux-Combe C, Aboulker JP, Taburet AM, Molina JM.

Antimicrob Agents Chemother. 2011 Jul;55(7):3613-5. doi: 10.1128/AAC.01827-10. Epub 2011 May 16.

16.

Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.

Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, de Castro N, Molina JM, Kuritzkes DR.

AIDS. 2011 Mar 13;25(5):665-9. doi: 10.1097/QAD.0b013e3283445834.

17.

Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.

Barrail-Tran A, Yazdanpanah Y, Goldwirt L, Chêne G, Colin C, Piketty C, Bollens D, Katlama C, Descamps D, Molina JM, Fagard C, Taburet AM; ANRS 139 study group.

AIDS. 2010 Oct 23;24(16):2581-3.

PMID:
20960678
18.

[Therapeutic drug monitoring].

Le Guellec C, Bentué-Ferrer D; groupe STP de la SFPT.

Therapie. 2010 Jan-Feb;65(1):13-5. French. No abstract available.

PMID:
20443240
19.

Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.

Barrail-Tran A, Mentré F, Cosson C, Piketty C, Chazallon C, Gérard L, Girard PM, Taburet AM.

Antimicrob Agents Chemother. 2010 Feb;54(2):614-9. doi: 10.1128/AAC.00797-09. Epub 2009 Dec 7.

20.

Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection.

Goldwirt L, Barrail-Tran A, Da Cruz M, Taburet AM, Furlan V.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Feb 1;878(3-4):456-60. doi: 10.1016/j.jchromb.2009.10.029. Epub 2009 Nov 11.

PMID:
19962949
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk